CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it will receive a written correspondence from the U.S. Food and Drug Administration (FDA) regarding its clinical program with arimoclomol as a treatment for amyotrophic lateral sclerosis.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Based on a brief telephone conversation with FDA representatives, CytRx is optimistic about the prospects of determining an acceptable pathway to resume the Phase IIb clinical development program, which CytRx may conduct through a strategic partnership. Although CytRx cannot control the timing of when it will receive the FDA’s letter, it expects to receive that correspondence in the second half of 2009.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
